An FDA advisory panel unanimously supported approval of telaprevir, Vertex Pharmaceuticals' drug candidate for hepatitis C. On Wednesday, advisers endorsed a similar drug, boceprevir, from Merck & Co. The protease inhibitors are proposed for use in combination with the standard therapy of pegylated interferon and ribavirin.

Full Story:

Related Summaries